drugset / Trial / NCT00211523
Safety and Efficacy of MBI 226 2.5% and 5.0% Topical Acne Solutions in the Treatment of Acne
RandomizedParallel-groupDouble-blindTreatment
Summary
This study investigates the safety and efficacy of MBI 226 2.5% and 5.0% Acne Solutions, applied topically for six weeks, in the treatment of acne.
Timeline
- Start
- 2000-10
- Primary completion
- —
- Completion
- 2001-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MBI 226 | Unknown | 2.5 % | Topical |
| Subject | MBI 226 | Unknown | 5 % | Topical |